Drugs / AM712
last change Nov 2024 re-read 3 minutes ago

AM712

also known as ASKG712

Protein / enzyme biologic

Developed for
wet macular degeneration
Investigated by
AffaMed Therapeutics Limited

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05345769 Apr 2022 → Nov 2024 wet macular degeneration AffaMed Therapeutics Limited Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AM712 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05345769 ↗
Known as ASKG712 “AM712(ASKG712)” NCT05345769 ↗
Action Inhibit “recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein” NCT05345769 ↗
Modality Protein / enzyme biologic “AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein” NCT05345769 ↗
Route Intravitreal “Following Intravitreal Administration” NCT05345769 ↗